Le Lézard
Classified in: Health
Subject: SVY

Cirrhosis - Global Clinical Trials Review H1, 2020


DUBLIN, April 1, 2020 /PRNewswire/ -- The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This clinical trial report, Cirrhosis Global Clinical Trials Review H1, 2020 provides an overview of Cirrhosis Clinical trials scenario.

The report provides top line data relating to the clinical trials on Cirrhosis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Report Scope

Reasons to Buy

Key Topics Covered

  1. Report Guidance
  2. Clinical Trials Report Coverage
  3. Clinical Trials by Region
  4. Clinical Trials and Average Enrollment by Country
  5. Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  6. Top Five Countries Contributing to Clinical Trials in Europe
  7. Top Countries Contributing to Clinical Trials in North America
  8. Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  9. Top Five Countries Contributing to Clinical Trials in Central and South America
  10. Clinical Trials by G7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  11. Clinical Trials by Phase in G7 Countries
  12. Clinical Trials in G7 Countries by Trial Status
  13. Clinical Trials by E7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  14. Clinical Trials by Phase in E7 Countries
  15. Clinical Trials in E7 Countries by Trial Status
  16. Clinical Trials by Phase
  17. In Progress Trials by Phase
  18. Clinical Trials by Trial Status
  19. Clinical Trials by End Point Status
  20. Subjects Recruited Over a Period of Time
  21. Clinical Trials by Sponsor Type
  22. Prominent Sponsors
  23. Top Companies Participating in Cirrhosis Therapeutics Clinical Trials
  24. Prominent Drugs
  25. Clinical Trial Profile Snapshots

Companies Mentioned

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/izj785

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: